Your browser doesn't support javascript.
loading
Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone.
Lorente, D; Omlin, A; Ferraldeschi, R; Pezaro, C; Perez, R; Mateo, J; Altavilla, A; Zafeirou, Z; Tunariu, N; Parker, C; Dearnaley, D; Gillessen, S; de Bono, J; Attard, G.
Afiliação
  • Lorente D; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton SM2 5PT, Surrey, UK.
  • Omlin A; 1] Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton SM2 5PT, Surrey, UK [2] Kantonsspital St. Gallen, Department of Oncology and Haematology, Rorschacherstrasse 95, CH-9007 St. Gallen, Sw
  • Ferraldeschi R; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton SM2 5PT, Surrey, UK.
  • Pezaro C; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton SM2 5PT, Surrey, UK.
  • Perez R; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton SM2 5PT, Surrey, UK.
  • Mateo J; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton SM2 5PT, Surrey, UK.
  • Altavilla A; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton SM2 5PT, Surrey, UK.
  • Zafeirou Z; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton SM2 5PT, Surrey, UK.
  • Tunariu N; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton SM2 5PT, Surrey, UK.
  • Parker C; Academic Urology Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton SM2 5PT, Surrey, UK.
  • Dearnaley D; Academic Urology Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton SM2 5PT, Surrey, UK.
  • Gillessen S; Kantonsspital St. Gallen, Department of Oncology and Haematology, Rorschacherstrasse 95, CH-9007 St. Gallen, Switzerland.
  • de Bono J; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton SM2 5PT, Surrey, UK.
  • Attard G; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton SM2 5PT, Surrey, UK.
Br J Cancer ; 111(12): 2248-53, 2014 Dec 09.
Article em En | MEDLINE | ID: mdl-25314055
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dexametasona / Prednisona / Neoplasias de Próstata Resistentes à Castração / Androstenos / Anti-Inflamatórios Tipo de estudo: Observational_studies Limite: Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: Br J Cancer Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dexametasona / Prednisona / Neoplasias de Próstata Resistentes à Castração / Androstenos / Anti-Inflamatórios Tipo de estudo: Observational_studies Limite: Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: Br J Cancer Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Reino Unido